Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 3
2008 3
2009 1
2010 1
2012 2
2013 3
2014 2
2015 4
2016 1
2017 4
2018 4
2019 3
2020 1
2021 1
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Free article. Clinical Trial.
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials.
Bayas A, Christ M, Faissner S, Klehmet J, Pul R, Skripuletz T, Meuth SG. Bayas A, et al. Among authors: klehmet j. Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221146836. doi: 10.1177/17562864221146836. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36710720 Free PMC article. Review.
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany - Baseline characteristics of the POWER@MS1 randomised controlled trial.
Krause N, Derad C, von Glasenapp B, Riemann-Lorenz K, Temmes H, van de Loo M, Friede T, Asendorf T, Heesen C; POWER@MS1 study group. Krause N, et al. Mult Scler Relat Disord. 2023 Nov;79:105043. doi: 10.1016/j.msard.2023.105043. Epub 2023 Oct 5. Mult Scler Relat Disord. 2023. PMID: 37839367 Free article. Clinical Trial.
[Public health situation of CIDP patients in nine German centers-neuritis network Germany].
Fisse AL, Motte J, Grüter T, Kohle F, Kronlage C, Stahl JH, Winter N, Seeliger T, Gingele S, Stascheit F, Hotter B, Klehmet J, Kummer K, Enax-Krumova EK, Sturm D, Skripuletz T, Schmidt J, Yoon MS, Pitarokoili K, Lehmann HC, Grimm A; Mitglieder des Neuritis Netz. Fisse AL, et al. Among authors: klehmet j. Nervenarzt. 2023 Apr;94(4):320-326. doi: 10.1007/s00115-022-01377-0. Epub 2022 Aug 23. Nervenarzt. 2023. PMID: 35997784 Free PMC article. German.
37 results